The American Society for Radiation Oncology guideline, built on a systematic review with graded recommendations, addresses four questions: bladder preservation with curative radiotherapy, radiotherapy technique and dose for intact disease, postoperative radiotherapy, and radiotherapy with non-curative intent.
For selected patients with cT2–4aN0M0 muscle-invasive bladder cancer, trimodal therapy is recommended as an alternative to radical cystectomy, with concurrent radiosensitising systemic therapy and neoadjuvant or induction systemic therapy for those at higher risk of distant progression. Whole-bladder radiotherapy at full dose, or reduced dose to uninvolved bladder with a partial boost, is recommended; elective nodal radiotherapy is conditional. After cystectomy, adjuvant radiotherapy is conditionally recommended for (y)pT3–4, node-positive or margin-positive urothelial carcinoma. IMRT with daily image guidance is recommended, and bladder-directed radiotherapy is recommended for high-burden metastatic or locally symptomatic disease.
For urologists, the practical shift is that bladder preservation should be discussed with suitable patients as a standard option, not only offered to those unfit for surgery. In India, where many patients decline cystectomy and urinary diversion, a formal trimodal pathway with multidisciplinary review gives them a guideline-backed alternative. The phrase 'select patients' matters: selection depends on complete resection, absence of extensive carcinoma in situ and hydronephrosis, and good bladder function.
- Discuss every muscle-invasive bladder cancer at a multidisciplinary meeting including radiation oncology
- Offer trimodal therapy as a curative alternative to cystectomy for suitable cT2–4aN0M0 patients
- Perform a maximal transurethral resection before trimodal therapy
- Give concurrent radiosensitising chemotherapy with radiotherapy
- Consider adjuvant radiotherapy after cystectomy for pT3–4, node-positive or margin-positive disease
Why it matters
Bladder preservation is now a guideline-endorsed curative option, not a fallback for patients unfit for surgery.
Don't overread it
The guideline endorses trimodal therapy for selected patients; it does not state that it is equivalent to cystectomy for all.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free